Navigation Links
Perrigo Granted Summary Judgment of Non-Infringement in Mucinex(R) Case
Date:2/12/2010

ALLEGAN, Mich., Feb. 12 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced today that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex® tablets. Perrigo had been sued by Adams Respiratory Therapeutics, Inc., (a subsidiary of Reckitt Benckiser Group plc.) the New Drug Application holder and patent owner. The United States District Court for the Western District of Michigan ruled today that Perrigo does not infringe the patent in the suit. Perrigo's ANDA is awaiting FDA approval.  

Perrigo’s Chairman and CEO Joseph C. Papa stated, “This is another example of Perrigo’s significant investment and commitment to bringing new store brand products to the market. This will be an important new store brand product addition in the cough/cold category to our retail and wholesale customers while providing significant savings for the U.S. consumer. Perrigo is working every day to make quality healthcare more affordable.”  

Mucinex® (guaifenesin extended-release tablets, 600 mg) an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $162 million through food, drug and mass merchandisers for the 12 months ended January 2010, as measured by ACNielsen.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company

RELATED LINKS
http://www.perrigo.com

'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, the premier multimedia ... launching its first bi-monthly issue of 2017 in February. The inaugural issue will ... One Health. , In making the announcement, American Veterinarian™ Publisher Chris Hennessy ...
(Date:2/21/2017)... ... February 21, 2017 , ... One of the most ... medical, mental health, and financial consequences of inaction. On March 3, World Hearing ... they have concerns about their hearing. , Effective treatment in the form of ...
(Date:2/20/2017)... ... 20, 2017 , ... MRI screening improves early diagnosis of breast cancer in ... online in the journal Radiology . , MRI has long been known ... ultrasound. Currently, guidelines reserve breast MRI screening for women who have a strong family ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the ... a visit this week at HIMSS 2017 Conference & Exhibition. The event brings ... Sensogram will be featured in the conference’s Connected Health Experience section, an area ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Ala. , Feb. 21, 2017 Auburn University ... major university to acquire a Hyperbaric Veterinary Medicine (HVM) Chamber.  ... chamber since 2012 in its small animal hospital, and now ... with a hyperbaric oxygen chamber that is engineered exclusively for ... to have its chambers in such highly revered universities like ...
(Date:2/21/2017)... YORK , Feb. 21, 2017 ... industry. This technique is allowing a previously unattainable ... simplicity. Due to this ability, it is anticipated ... cross US$ 4 Billion by 2022. The growth ... by advancements in computing platforms, rising installation of ...
(Date:2/21/2017)... BEACH, Va. , Feb. 21, 2017  Global ... now covers Dermacell ® for breast ... foot ulcers. Dermacell is an advanced acellular dermal matrix ... Technologies, Inc. (NASDAQ: NVDQ ) ... the four major commercial health-care payers to review the ...
Breaking Medicine Technology: